Home Immunization with Palivizumab-A Randomized Pilot Study Describing Safety Aspects and Parents’ Preferences
Abstract
:1. Introduction
2. Materials and Methods
2.1. Design
2.2. Participants
2.3. Settings
2.4. Ethics
2.5. Safety Aspects
2.6. Data Collection
2.7. Data Analysis
2.8. Trustworthiness
3. Results
3.1. Safety Aspects
3.2. Parental Preferences and Motives
3.2.1. Protect and Watch over the Infant
The Clinic-Based Settings’ Environment as a Threat and Protection
Avoid Public Places
3.2.2. Optimal Health and Well-Being for the Whole Family
Functional Living Conditions
Parental Involvement in Decision-Making
3.2.3. Avoid Suffering for the Infant
The Home Environment as a Secure and Safe Place
The Infant’s Sensitivity to Disturbances
4. Discussion
5. Strengths and Limitations
6. Conclusions
7. Implications for Practice
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Nair, H.; Nokes, D.J.; Gessner, B.D.; Dherani, M.; Madhi, S.A.; Singleton, R.J.; O’Brien, K.L.; Roca, A.; Wright, P.F.; Bruce, N.; et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet 2010, 375, 1545–1555. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Granbom, E.; Fernlund, E.; Sunnegårdh, J.; Lundell, B.; Naumburg, E. Respiratory Tract Infection and Risk of Hospitalization in Children with Congenital Heart Defects During Season and Off-Season: A Swedish National Study. Pediatr. Cardiol. 2016, 37, 1098–1105. [Google Scholar] [CrossRef] [PubMed]
- Hong, T.; Bolisetty, S.; Bajuk, B.; Abdel-Latif, M.; Oei, J.; Jaffe, A.; Lui, K. A population study of respiratory rehospitalization in very preterm infants in the first 3 years of life. J. Paediatr. Child Health 2016, 52, 715–721. [Google Scholar] [CrossRef] [PubMed]
- Régnier, S.A.; Huels, J. Association between respiratory syncytial virus hospitalizations in infants and respiratory sequelae: Systematic review and meta-analysis. Pediatr. Infect. Dis. J. 2013, 32, 820–826. [Google Scholar] [CrossRef] [PubMed]
- Shi, T.; Balsells, E.; Wastnedge, E.; Singleton, R.; Rasmussen, Z.A.; Zar, H.J.; Rath, B.A.; Madhi, S.A.; Campbell, S.; Vaccari, L.C.; et al. Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: Systematic review and meta-analysis. J. Glob. Health 2015, 5, 020416. [Google Scholar] [CrossRef]
- Sommer, C.; Resch, B.; Simões, E.A. Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbiol. J. 2011, 5, 144–154. [Google Scholar] [CrossRef] [Green Version]
- DiFranza, J.R.; Masaquel, A.; Barrett, A.M.; Colosia, A.D.; Mahadevia, P.J. Systematic literature review assessing tobacco smoke exposure as a risk factor for serious respiratory syncytial virus disease among infants and young children. BMC Pediatr. 2012, 12, 81. [Google Scholar] [CrossRef] [Green Version]
- Langkamp, D.L.; Hlavin, S.M. Factors predicting compliance with palivizumab in high-risk infants. Am. J. Perinatol. 2001, 18, 345–352. [Google Scholar] [CrossRef]
- Andabaka, T.; Nickerson, J.W.; Rojas-Reyes, M.X.; Rueda, J.D.; Bacic Vrca, V.; Barsic, B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst. Rev. 2013, Cd006602. [Google Scholar] [CrossRef]
- Swedish Medical Products Agency. Available online: https://lakemedelsverket.se/english/ (accessed on 10 January 2019).
- Chen, J.J.; Chan, P.; Paes, B.; Mitchell, I.; Li, A.; Lanctôt, K.L.; CARESS Investigators. Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention. PLoS ONE 2015, 10, e0134711. [Google Scholar] [CrossRef]
- Feltes, T.F.; Cabalka, A.K.; Meissner, H.C.; Piazza, F.M.; Carlin, D.A.; Top, F.H., Jr.; Connor, E.M.; Sondheimer, H.M.; for the Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J. Pediatr. 2003, 143, 532–540. [Google Scholar] [CrossRef] [Green Version]
- Wegzyn, C.; Toh, L.K.; Notario, G.; Biguenet, S.; Unnebrink, K.; Park, C.; Makari, D.; Norton, M. Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review. Infect. Dis. Ther. 2014, 3, 133–158. [Google Scholar] [CrossRef] [Green Version]
- Frogel, M.; Nerwen, C.; Boron, M.; Cohen, A.; VanVeldhuisen, P.; Harrington, M.; Groothuis, J. Improved outcomes with home-based administration of palivizumab: Results from the 2000–2004 Palivizumab Outcomes Registry. Pediatr. Infect. Dis. J. 2008, 27, 870–873. [Google Scholar] [CrossRef]
- Golombek, S.G.; Berning, F.; Lagamma, E.F. Compliance with prophylaxis for respiratory syncytial virus infection in a home setting. Pediatr. Infect. Dis. J. 2004, 23, 318–322. [Google Scholar] [CrossRef]
- Hand, I.L.; Noble, L.; Geiss, D.; Shotkin, A. Respiratory syncytial virus immunoprophylaxis in an urban population: A comparison of delivery strategies and outcomes. Pediatr. Infect. Dis. J. 2008, 27, 175–176. [Google Scholar] [CrossRef]
- Krippendorff, K. Content Analysis: An Introduction to Its Methodology, 4th ed.; SAGE: Thousand Oaks, CA, USA, 2019. [Google Scholar]
- Groothuis, J.R.; Hoopes, J.M.; Hemming, V.G. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis. Adv. Ther. 2011, 28, 110–125. [Google Scholar] [CrossRef] [Green Version]
- The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102 Pt 1, 531–537. [Google Scholar] [CrossRef]
- Savitz, J.; Geaney, C.; Banks, T.A. A case of anaphylaxis to palivizumab. Ann. Allergy Asthma Immunol. 2014, 113, 236–237. [Google Scholar] [CrossRef]
- Lacaze-Masmonteil, T.; Seidenberg, J.; Mitchell, I.; Cossey, V.; Cihar, M.; Csader, M.; Baarsma, R.; Valido, M.; Pollack, P.F.; Groothuis, J.R. Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection. Drug Saf. 2003, 26, 283–291. [Google Scholar] [CrossRef]
- Maser, E.A.; Villela, R.; Silverberg, M.S.; Greenberg, G.R. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin. Gastroenterol. Hepatol. 2006, 4, 1248–1254. [Google Scholar] [CrossRef]
- Mori, F.; Saretta, F.; Bianchi, A.; Crisafulli, G.; Caimmi, S.; Liotti, L.; Bottau, P.; Franceschini, F.; Paglialunga, C.; Ricci, G.; et al. Hypersensitivity Reactions to Monoclonal Antibodies in Children. Medicina 2020, 56, 232. [Google Scholar] [CrossRef] [PubMed]
- Lasiuk, G.C.; Comeau, T.; Newburn-Cook, C. Unexpected: An interpretive description of parental traumas’ associated with preterm birth. BMC Pregnancy Childbirth 2013, 13 (Suppl. 1), S13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Day, K.L.; Schmidt, L.A.; Vaillancourt, T.; Saigal, S.; Boyle, M.H.; Van Lieshout, R.J. Overprotective Parenting and Peer Victimization in Extremely Low Birth Weight Survivors. J. Child Fam. Stud. 2018, 27, 907–915. [Google Scholar] [CrossRef] [PubMed]
- Garfield, C.F.; Lee, Y.; Kim, H.N. Paternal and maternal concerns for their very low-birth-weight infants transitioning from the NICU to home. J. Perinat. Neonatal Nurs. 2014, 28, 305–312. [Google Scholar] [CrossRef] [PubMed]
- Murdoch, M.R.; Franck, L.S. Gaining confidence and perspective: A phenomenological study of mothers’ lived experiences caring for infants at home after neonatal unit discharge. J. Adv. Nurs. 2012, 68, 2008–2020. [Google Scholar] [CrossRef]
- Whelan, B.; Musters, E.; Murray, A.; Moore, E.; Lievaart, L.; Visser, S.; Toxopeus, E.; van Veen, A.; Notario, G.; Campbell, F.J. Review of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The Netherlands. Drugs Ther. Perspect. 2016, 32, 119–130. [Google Scholar] [CrossRef] [Green Version]
- Jackson, K.; Ternestedt, B.M.; Schollin, J. From alienation to familiarity: Experiences of mothers and fathers of preterm infants. J. Adv. Nurs. 2003, 43, 120–129. [Google Scholar] [CrossRef]
- Treyvaud, K.; Doyle, L.W.; Lee, K.J.; Roberts, G.; Cheong, J.L.; Inder, T.E.; Anderson, P.J. Family functioning, burden and parenting stress 2 years after very preterm birth. Early Hum. Dev. 2011, 87, 427–431. [Google Scholar] [CrossRef]
- Kersting, A.; Dorsch, M.; Wesselmann, U.; Lüdorff, K.; Witthaut, J.; Ohrmann, P.; Hörnig-Franz, I.; Klockenbusch, W.; Harms, E.; Arolt, V. Maternal posttraumatic stress response after the birth of a very low-birth-weight infant. J. Psychosom. Res. 2004, 57, 473–476. [Google Scholar] [CrossRef]
- Holditch-Davis, D.; Bartlett, T.R.; Blickman, A.L.; Miles, M.S. Posttraumatic stress symptoms in mothers of premature infants. J. Obstet. Gynecol. Neonatal Nurs. 2003, 32, 161–171. [Google Scholar] [CrossRef]
- McLean, A.; Townsend, A.; Clark, J.; Sawyer, M.G.; Baghurst, P.; Haslam, R.; Whaites, L. Quality of life of mothers and families caring for preterm infants requiring home oxygen therapy: A brief report. J. Paediatr. Child Health 2000, 36, 440–444. [Google Scholar] [CrossRef]
- Cleveland, L.M. Parenting in the neonatal intensive care unit. J. Obstet. Gynecol. Neonatal Nurs. 2008, 37, 666–691. [Google Scholar] [CrossRef]
- Wigert, H.; Dellenmark Blom, M.; Bry, K. Parents’ experiences of communication with neonatal intensive-care unit staff: An interview study. BMC Pediatr. 2014, 14, 304. [Google Scholar] [CrossRef] [Green Version]
- Ekman, I.; Swedberg, K.; Taft, C.; Lindseth, A.; Norberg, A.; Brink, E.; Carlsson, J.; Dahlin-Ivanoff, S.; Johansson, I.L.; Kjellgren, K.; et al. Person-centered care—Ready for prime time. Eur. J. Cardiovasc. Nurs. 2011, 10, 248–251. [Google Scholar] [CrossRef]
- Weis, J.; Zoffmann, V.; Egerod, I. Enhancing person-centred communication in NICU: A comparative thematic analysis. Nurs. Crit. Care 2015, 20, 287–298. [Google Scholar] [CrossRef]
- Seppänen, A.V.; Sauvegrain, P.; Draper, E.S.; Toome, L.; El Rafei, R.; Petrou, S.; Barros, H.; Zimmermann, L.J.I.; Cuttini, M.; Zeitlin, J.; et al. Parents’ ratings of post-discharge healthcare for their children born very preterm and their suggestions for improvement: A European cohort study. Pediatr. Res. 2021, 89, 1004–1012. [Google Scholar] [CrossRef]
- Narayan, O.; Bentley, A.; Mowbray, K.; Hermansson, M.; Pivonka, D.; Kemadjou, E.N.; Belsey, J. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK. J. Med. Econ. 2020, 23, 1640–1652. [Google Scholar] [CrossRef]
- Neovius, K.; Buesch, K.; Sandström, K.; Neovius, M. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden. Acta Paediatr. 2011, 100, 1306–1314. [Google Scholar] [CrossRef]
- Wang, D.; Bayliss, S.; Meads, C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: A systematic review and additional economic modelling of subgroup analyses. Health Technol. Assess. 2011, 15, 1–124. [Google Scholar] [CrossRef] [Green Version]
- Valeri, B.O.; Holsti, L.; Linhares, M.B. Neonatal pain and developmental outcomes in children born preterm: A systematic review. Clin. J. Pain 2015, 31, 355–362. [Google Scholar] [CrossRef]
- Vinall, J.; Miller, S.P.; Synnes, A.R.; Grunau, R.E. Parent behaviors moderate the relationship between neonatal pain and internalizing behaviors at 18 months corrected age in children born very prematurely. Pain 2013, 154, 1831–1839. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ullsten, A.; Andreasson, M.; Eriksson, M. State of the Art in Parent-Delivered Pain-Relieving Interventions in Neonatal Care: A Scoping Review. Front. Pediatr. 2021, 9, 651846. [Google Scholar] [CrossRef] [PubMed]
- Allen, E.C.; Manuel, J.C.; Legault, C.; Naughton, M.J.; Pivor, C.; O’Shea, T.M. Perception of child vulnerability among mothers of former premature infants. Pediatrics 2004, 113, 267–273. [Google Scholar] [CrossRef] [PubMed]
Characteristics | All n = 43 | IG n = 23 | CG n = 20 |
---|---|---|---|
Gestational age, weeks, median (range) | 27 (23–41) | 26 (23–40) | 27.5 (24–41) |
Gestational weight, kg, median, (range) | 0.935 (0.482–3.65) | 0.915 (0.482–3.63) | 1.075 (0.656–3.65) |
Sex female/male (n) | 21/22 | 12/11 | 9/11 |
Age at start of immunization, months, uncorrected median (range) | 8 (1.9-25) | 8 (2.5–20.1) | 8 (1.9–25) |
BPD diagnosis (n) | 34 | 20 | 14 |
CHD diagnosis or other circulatory disorder (n) | 7 | 2 | 5 |
Other diagnosis * (n) | 2 | 1 | 1 |
Medication for respiratory a/o circulatory disorder (n) | 16 | 8 | 8 |
Oxygen treatment (n) | 2 | 2 | 0 |
Second immunization period (n) | 10 | 8 | 2 |
Verified RSV infection during immunization period (n) | 0 | 0 | 0 |
Older siblings (yes, n) | 20 | 11 | 9 |
Exposure to tobacco in home (n) | 3 | 1 | 2 |
Smoking mother during pregnancy and/or breastfeeding (n) | 1 | 0 | 1 |
Starting kindergarten during studied season (n) | 3 | 3 | 0 |
Subcategories | Core Categories |
---|---|
The clinic-based settings’ environment as a threat and protection | Protect and watch over the infant |
Avoid public places | |
Functional living conditions | Optimal health and well-being for the whole family |
Parental involvement in decision-making | |
The home environment as a secure and safe place | Avoid suffering for the infant |
The infant’s sensitivity to disturbances |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ebersjö, C.; Berggren Broström, E.; Kull, I.; Lindholm Olinder, A. Home Immunization with Palivizumab-A Randomized Pilot Study Describing Safety Aspects and Parents’ Preferences. Children 2023, 10, 198. https://doi.org/10.3390/children10020198
Ebersjö C, Berggren Broström E, Kull I, Lindholm Olinder A. Home Immunization with Palivizumab-A Randomized Pilot Study Describing Safety Aspects and Parents’ Preferences. Children. 2023; 10(2):198. https://doi.org/10.3390/children10020198
Chicago/Turabian StyleEbersjö, Christina, Eva Berggren Broström, Inger Kull, and Anna Lindholm Olinder. 2023. "Home Immunization with Palivizumab-A Randomized Pilot Study Describing Safety Aspects and Parents’ Preferences" Children 10, no. 2: 198. https://doi.org/10.3390/children10020198
APA StyleEbersjö, C., Berggren Broström, E., Kull, I., & Lindholm Olinder, A. (2023). Home Immunization with Palivizumab-A Randomized Pilot Study Describing Safety Aspects and Parents’ Preferences. Children, 10(2), 198. https://doi.org/10.3390/children10020198